Detalhe da pesquisa
1.
Natural cubic splines for the analysis of Alzheimer's clinical trials.
Pharm Stat
; 22(3): 508-519, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36627206
2.
The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
Alzheimers Dement
; 19(4): 1227-1233, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35971310
3.
A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease.
Stat Med
; 37(21): 3047-3055, 2018 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29761523
4.
A phase 3 trial of semagacestat for treatment of Alzheimer's disease.
N Engl J Med
; 369(4): 341-50, 2013 Jul 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-23883379
5.
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
Alzheimers Dement
; 12(2): 110-120, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26238576
6.
Adverse events and dropouts in Alzheimer's disease studies: what can we learn?
Alzheimers Dement
; 11(1): 24-31, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24613705
7.
Assessment of type I error rate associated with dose-group switching in a longitudinal Alzheimer trial.
J Biopharm Stat
; 24(3): 660-84, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24697817
8.
Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies.
Alzheimers Dement
; 8(5): 407-16, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22138370
9.
Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.
Alzheimers Dement
; 8(4): 261-71, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22672770
10.
Representativeness of European clinical trial populations in mild Alzheimer's disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study.
Alzheimers Res Ther
; 10(1): 36, 2018 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29615123
11.
Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes.
Schizophr Res
; 86(1-3): 300-8, 2006 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16860974
12.
A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia.
Schizophr Res
; 79(2-3): 337-40, 2005 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16054802
13.
Impulsive aggression with irritability and responsive to divalproex: a pediatric bipolar spectrum disorder phenotype?
J Affect Disord
; 88(3): 279-85, 2005 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16169087
14.
Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years.
Alzheimers Dement (N Y)
; 1(2): 111-121, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29854931
15.
Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer's disease.
Alzheimers Res Ther
; 7(1): 36, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26064192
16.
Combination pharmacotherapy in children and adolescents with bipolar disorder.
Biol Psychiatry
; 53(11): 978-84, 2003 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12788243
17.
Donors with central nervous system malignancies: are they truly safe?
Transplantation
; 76(2): 340-3, 2003 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-12883189
18.
Neuroendocrine and behavioral responses to dopaminergic agonists in adolescents with alcohol abuse.
Psychopharmacology (Berl)
; 166(2): 95-101, 2003 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-12520313
19.
Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial.
J Am Acad Child Adolesc Psychiatry
; 43(2): 206-14, 2004 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-14726728
20.
Effect of weight change on bone mass in female adolescents.
J Am Diet Assoc
; 103(3): 369-72, 2003 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-12616262